Literature DB >> 15139568

National prevalence of respiratory allergic disorders.

R Dahl1, P S Andersen, T Chivato, E Valovirta, J de Monchy.   

Abstract

BACKGROUND: Many epidemiological studies have assessed the prevalence of respiratory allergic disorders in confined geographical locations. However, no study has yet established nationally prevalence data in a uniform manner representing whole countries and, thus, enabling cross-national comparisons.
METHODS: In 10 European countries, screening of random, representative samples of telephone numbers identified the target population aged 16-60. The inclusion criteria were a positive reporting of respiratory allergy to named allergens and, concomitantly, an unassisted description of appropriate symptoms. To obtain a truly representative, national prevalence of each country, the data were weighted against the actual sex and age composition.
RESULTS: 31,065 screening interviews were performed. The nationally balanced prevalence varied significantly among the 10 countries (P<0.001) from 11.7% in Spain to 33.6% in Italy. The overall weighted prevalence for Europe was 24.4%. Comparing males and females, overall, the odds-ratio was 0.874 (P<0.001). For age intervals of 16-29, 30-49, and 50-60 years, the odds-ratios for males were 1.104 (P<0.088), 0.827 (P<0.001), and 0.658 (P<0.001), respectively. The prevalence correlated inversely with age.
CONCLUSIONS: Respiratory allergic disorders constitute a huge health problem in Europe, and the impact may be increasing as the prevalence is highest among young people.

Entities:  

Mesh:

Year:  2004        PMID: 15139568     DOI: 10.1016/j.rmed.2003.11.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

1.  Mucosal bromodomain-containing protein 4 mediates aeroallergen-induced inflammation and remodeling.

Authors:  Bing Tian; Koa Hosoki; Zhiqing Liu; Jun Yang; Yingxin Zhao; Hong Sun; Jia Zhou; Erik Rytting; Lata Kaphalia; William J Calhoun; Sanjiv Sur; Allan R Brasier
Journal:  J Allergy Clin Immunol       Date:  2018-10-13       Impact factor: 10.793

2.  The Prevalence, Risk Factors and Changes in Symptoms of Self Reported Asthma, Rhinitis and Eczema Among Pregnant Women in Ogbomoso, Nigeria.

Authors:  Adewale Samson Adeyemi; Adeolu Oladayo Akinboro; Philip Babatunde Adebayo; Moses O Tanimowo; Olugbenga Edward Ayodele
Journal:  J Clin Diagn Res       Date:  2015-09-01

3.  Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis.

Authors:  Steen M Rønborg; Ulrik G Svendsen; Jesper S Micheelsen; Lars Ytte; Jakob N Andreasen; Lars Ehlers
Journal:  Clinicoecon Outcomes Res       Date:  2012-09-11

4.  Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.

Authors:  Sabina Rak; William H Yang; Martin R Pedersen; Stephen R Durham
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 3.440

5.  Mucosal exposure to cockroach extract induces allergic sensitization and allergic airway inflammation.

Authors:  Narcy G Arizmendi; Melanie Abel; Lakshmi Puttagunta; Muhammad Asaduzzaman; Courtney Davidson; Khalil Karimi; Paul Forsythe; Harissios Vliagoftis
Journal:  Allergy Asthma Clin Immunol       Date:  2011-12-14       Impact factor: 3.406

Review 6.  Asthma out of control? A structured review of recent patient surveys.

Authors:  Stephen T Holgate; David Price; Erkka Valovirta
Journal:  BMC Pulm Med       Date:  2006-11-30       Impact factor: 3.317

7.  Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists' Consensus.

Authors:  Carmen Vidal; Ernesto Enrique; Angeles Gonzalo; Carmen Moreno; Ana I Tabar
Journal:  Clin Transl Allergy       Date:  2014-11-07       Impact factor: 5.871

8.  Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax®.

Authors:  Moisés Calderón; Tove Brandt
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

9.  Managing co-morbid asthma with allergic rhinitis: targeting the one-airway with leukotriene receptor antagonists.

Authors:  Erkka Valovirta
Journal:  World Allergy Organ J       Date:  2012-04-17       Impact factor: 4.084

10.  (Un)Awareness of allergy.

Authors:  A Fusun Kalpaklioglu; Ilkay Koca Kalkan; Ahmet Akcay; Ismail Reisli; Demet Can; Nevin Uzuner; Hasan Yuksel; Cengiz Kirmaz; Figen Gulen; Dane Ediger
Journal:  World Allergy Organ J       Date:  2011-11-18       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.